Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ADC Therapeutics SA ADCT

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NYSE:ADCT)

Fundamentals Snapshot (NYSE:ADCT)

Current News (NYSE:ADCT)

ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

Business Wire 2 days ago

ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022

Business Wire 9 days ago

ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors

Business Wire July 27, 2022

ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma

Business Wire July 20, 2022

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial

Business Wire July 11, 2022

ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories

Business Wire July 8, 2022

ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors

Business Wire July 1, 2022

ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents

Business Wire June 29, 2022

ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer

Business Wire June 13, 2022

Opinion & Analysis (NYSE:ADCT)

No current opinion is available.

Bullboard Posts (NYSE:ADCT)